Tema ETFs’s Alnylam Pharmaceuticals ALNY Stock Holding History

Tema ETFs’s Portfolio ALNY Stock Details ALNY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$629K	Buy	2,549 +619	+32%	+$158K	0.02%	377
2026 Q2	$581K	Sell	1,930 -42	-2%	-$12.7K	0.02%	387
2026 Q1	$652K	Sell	1,972 -24	-1%	-$8.17K	0.04%	313
2025 Q4	$794K	Sell	1,996 -567	-22%	-$251K	0.06%	276
2025 Q3	$1.17M	Sell	2,563 -2,738	-52%	-$1.11M	0.1%	231
2025 Q2	$1.73M	Sell	5,301 -1,174	-18%	-$325K	0.46%	78
2025 Q1	$1.75M	Sell	6,475 -9,848	-60%	-$2.53M	0.52%	68
2024 Q4	$3.84M	Buy	+16,323	New	+$4.29M	1.59%	24

Other funds holding ALNY

Assenagon Asset Management Senningerberg, Luxembourg $103B AUM 40.17% 1-Year Est. Return

Fjarde Ap-fonden Stockholm, Sweden $19.4B AUM 31.69% 1-Year Est. Return

MN Services Vermogensbeheer The Hague, Netherlands $13.4B AUM 37.34% 1-Year Est. Return

IFM Investors Melbourne, Australia $16B AUM 33.69% 1-Year Est. Return

Portman Square Capital London, United Kingdom $1.77B AUM 15.29% 1-Year Est. Return

PensionDanmark Copenhagen O, Denmark $12.3B AUM 33.99% 1-Year Est. Return

AssetMark Inc Concord, California $59.5B AUM 15.92% 1-Year Est. Return

Sumitomo Mitsui DS Asset Management Tokyo, Japan $14.8B AUM 30.39% 1-Year Est. Return

Robeco Institutional Asset Management Rotterdam, Netherlands $83.2B AUM 35.34% 1-Year Est. Return

Wealth Enhancement Advisory Services Plymouth, Minnesota $67.3B AUM 21.9% 1-Year Est. Return

Tema ETFs's ALNY Position: Q3 2026 in Review

Tema ETFs increased its Alnylam Pharmaceuticals (ALNY) stake by 32% in Q3 2026, buying an estimated $158K and bringing the position to 2,549 shares worth $629K. The position accounts for 0.02% of the portfolio, ranked #377.

Tema ETFs first reported a position in ALNY in Q4 2024 and has held it in 8 quarters since. The position peaked at $3.84M in Q4 2024. 102 funds tracked by Wall St. Rank hold ALNY as of Q3 2026.

Tema ETFs held 2,549 shares of Alnylam Pharmaceuticals worth $629K as of Q3 2026.
Tema ETFs bought 619 Alnylam Pharmaceuticals shares in Q3 2026, an estimated $158K.
Alnylam Pharmaceuticals made up 0.02% of Tema ETFs's portfolio in Q3 2026, its #377 holding.
Tema ETFs first reported a position in Alnylam Pharmaceuticals in Q4 2024 and has held it in 8 quarters since.
Tema ETFs's Alnylam Pharmaceuticals position peaked at $3.84M in Q4 2024.
102 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q3 2026.

Based on Tema ETFs's 13F filing for Q3 2026, filed 16 Oct 2026.